advertisement
Goldberg JL 23
Showing records 1 to 23 | Display all abstracts from Goldberg JL108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Sun Y
Ophthalmology science 2023; 3: 100290
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Johnson TV
iScience 2023; 26: 106361
108604 Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement
Goldberg JL; Beykin G
Ophthalmology science 2023; 3: 100298
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Calkins DJ
iScience 2023; 26: 106361
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Wirta D
Ophthalmology science 2023; 3: 100290
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Fortune B
iScience 2023; 26: 106361
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Murahashi W
Ophthalmology science 2023; 3: 100290
108604 Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement
Satterfield KR; Nuñez M
Ophthalmology science 2023; 3: 100298
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Mathur V
Ophthalmology science 2023; 3: 100290
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Goldberg JL; La Torre A
iScience 2023; 26: 106361
108604 Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement
Lam BL
Ophthalmology science 2023; 3: 100298
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Sankaranarayanan S; Sankaranarayanan S; Taylor LK
Ophthalmology science 2023; 3: 100290
108604 Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement
Albini TA
Ophthalmology science 2023; 3: 100298
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Taylor LK
Ophthalmology science 2023; 3: 100290
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Lamba DA
iScience 2023; 26: 106361
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Yednock T
Ophthalmology science 2023; 3: 100290
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Meyer JS
iScience 2023; 26: 106361
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Yednock T
Ophthalmology science 2023; 3: 100290
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Reh TA
iScience 2023; 26: 106361
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Fong DS
Ophthalmology science 2023; 3: 100290
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Wallace VA
iScience 2023; 26: 106361
108538 Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma
Goldberg JL
Ophthalmology science 2023; 3: 100290
108296 The importance of unambiguous cell origin determination in neuronal repopulation studies
Zack DJ; Baranov P
iScience 2023; 26: 106361
